Millennium Management LLC Increases Stake in ABIVAX Société Anonyme (NASDAQ:ABVX)

Millennium Management LLC raised its holdings in shares of ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) by 44.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 931,179 shares of the company's stock after acquiring an additional 285,542 shares during the period. Millennium Management LLC owned approximately 1.47% of ABIVAX Société Anonyme worth $6,816,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Kennedy Capital Management LLC raised its position in ABIVAX Société Anonyme by 0.7% during the fourth quarter. Kennedy Capital Management LLC now owns 225,470 shares of the company's stock valued at $1,650,000 after acquiring an additional 1,656 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of ABIVAX Société Anonyme by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock valued at $41,000 after purchasing an additional 1,990 shares in the last quarter. R Squared Ltd purchased a new position in shares of ABIVAX Société Anonyme during the 4th quarter valued at approximately $36,000. BNP Paribas Financial Markets lifted its stake in shares of ABIVAX Société Anonyme by 47.5% in the 4th quarter. BNP Paribas Financial Markets now owns 19,244 shares of the company's stock valued at $141,000 after purchasing an additional 6,200 shares during the period. Finally, Ameriprise Financial Inc. purchased a new stake in ABIVAX Société Anonyme during the fourth quarter worth $85,000. 47.91% of the stock is owned by hedge funds and other institutional investors.

ABIVAX Société Anonyme Price Performance

ABIVAX Société Anonyme stock traded down $0.04 during trading on Friday, reaching $5.98. The company had a trading volume of 73,375 shares, compared to its average volume of 189,346. The firm's 50-day simple moving average is $6.25 and its 200 day simple moving average is $6.98. ABIVAX Société Anonyme has a 1-year low of $4.77 and a 1-year high of $14.70.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. JMP Securities restated a "market outperform" rating and set a $33.00 price target on shares of ABIVAX Société Anonyme in a research report on Wednesday, April 30th. Morgan Stanley restated an "equal weight" rating and set a $12.00 target price on shares of ABIVAX Société Anonyme in a research report on Thursday, March 20th.

ABIVAX Société Anonyme Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.